News & Insights (Pharmaceutical Law)

Advocate General recommends that the ECJ dismiss AstraZeneca's appeal against Losec antitrust decision

Last year, we reported on AstraZeneca's decision to appeal to the European Court of Justice (ECJ) against a finding by the ...

NHS Primary Care Trusts challenged in the UK for use of cheaper drug off-licence

Novartis announced on Tuesday that it is seeking a judicial review of a decision made by four NHS Primary Care Trusts to approve ...

Cross border injunctions possible in patent cases says Advocate General

Cross border injunctions possible in patent cases says Advocate General C 616/10 Solvay SA v Honeywell Fluorine Products ...

UK Government consults on “above the line” research and development

The Government announced in its Autumn Statement in November 2011 that it would consult on the introduction of an 'above the ...

The unitary European patent and the unified European patent litigation system - no political agreement but still opportunities to have your say

There have been no developments of any significance towards finalising agreement on the "EU patent package” (unitary patent, ...

Employees on Twitter – strict liability for pharma?

A recent ruling by the Prescription Medicines Code of Practice Authority (the “PMCPA”) has illustrated the challenges that ...

Patent infringement in the UK and Europe

Usage patents, carve-outs, skinny labelling and off-label prescribing The competitive environment in which life sciences ...

Quetiapine patent, for sustained release formulations, invalid in the UK

Mr. Justice Arnold handed down judgment of the UK High Court today declaring patent EP (UK) 0 907 364 invalid for obviousness. ...

InFocus: Life Sciences & Healthcare e-newsletter - January 2012

Welcome to the January issue of InFocus, our life sciences and healthcare e-newsletter. In this issue we look at: ...

A unitary European patent and a unified European patent litigation system – still no political agreement

The latest news is that the so-called Warsaw Convention was not signed on 22 December.  According to the press release from ...

Contract Law Review 2011

As ever, contractual disputes have kept the English courts busy in 2011.  Here is a quick roundup of some of the ...

Life Sciences Review of the Year 2011, and a Preview of 2012

2011 was a year in which the UK life sciences industry has had much to consider: the NHS reforms, the Government’s Strategy for ...

A unitary European patent and a unified European patent litigation system – political agreement by the end of 2011?

Following on from our report in October and our article in BSLR*, Poland which currently holds the rotating presidency of the ...

SPCs for combination products - where are we now and what’s ahead in 2012?

There has been a multitude of references to the European Court of Justice (ECJ) to determine how and under what conditions, SPCs ...

New framework for provision of information to the general public about prescription-only medicines

We have followed the development and reported on proposals for amendments to EU legislation relating to prescription-only ...

Negative and zero term SPCs OK says the ECJ

Merck & Co. Inc. v Deutsches Patent- und Markenamt (Case C-125/10) ECJ decide on negative / zero term SPCs and the starting ...

SPCs for combination products: Clarification from the ECJ today?

In the October issue of our life sciences and healthcare eBulletin, InFocus, we set out the background and discussed Advocate ...

News on the Patent Box and the R&D tax credit proposals

HM Treasury is expected to publish draft legislation on 6th December 2011, covering both the Patent Box and the R&D tax ...

InFocus: Life Sciences & Healthcare e-newsletter - October 2011

Welcome to the October issue of InFocus, our life sciences and healthcare e-newsletter. In this issue we look ...

A unitary European patent and a unified European patent litigation system – political agreement by the end of 2011?

Unitary Patent As we reported in the July InFocus draft regulations were published on the establishment of a unitary European ...

Advocate General's Opinion in SPC referral - infringement test rejected

As previously reported in our e-newsletters, InFocus - January 2011 and InFocus - October 2010, there have been a number of ...

InFocus: Life Sciences & Healthcare e-newsletter - July 2011

Welcome to the July issue of InFocus, our life sciences and healthcare e-newsletter. In this issue we look at: ...

EU Patent and unified patent litigation system - Update July 2011

Despite the tortuous route to a unified patent and a unified patent litigation court in Europe, both now appear to be a small ...

Social Media and Pharma in the UK: a Review of the Pitfalls and the Latest Guidance

Social media channels are the latest and most dynamic and interactive marketing tools available to business, but in the UK most ...

Clause with teeth: Rights of First Refusal and Liability Caps

Right of first refusal clauses are by no means uncommon in commercial contracts.  But they are relatively rarely ...

HM Treasury consults further on the Patent Box and R&D tax credits

The anticipated consultation on the Patent Box was finally published by HM Treasury on 10 June 2011 together with a linked ...

Negative and zero term SPCs OK says Advocate General

Merck & Co Inc v Deutsches Patent- und Markenamt (Case C-125/10) In his opinion on 9 June 2011, Advocate General Yves Bot ...

Informal consultation on the UK bolar and research exemptions

In its Plan for Growth published in March, the UK Government committed to ensure that the intellectual property system in the UK ...

Jurisdictional arrangements for the EU patent to be discussed at the EU Competiveness Council meeting next week

Following the publication by the Commission of the draft regulations necessary to implement unitary patent protection on 13 April ...

UK healthcare reforms and the "Plan for Growth"

Improved healthcare means opportunities for life sciences and healthcare companies Successive UK governments have recognised ...

Taylor Wessing presents on EGA Pre-Conference Seminar

Double partner hire in IP for Taylor Wessing

Following the recent news of Niki Walker's appointment as a new partner to the Employment & Pensions group, international law ...

The Bribery Act 2010 – How will it impact the pharmaceutical industry?

At a time when the value of emerging markets to the pharmaceutical industry is increasing, the global reach of the Bribery Act ...

You never give me your money: Competition law, damages actions, and the healthcare sector

Public healthcare bodies that have suffered loss as a result of competition law infringements should consider ‘follow on’ damages ...

Taylor Wessing advises on creation of global leader in innovative drug discovery

Taylor Wessing is advising SuperGen, Inc., a NASDAQ listed pharmaceutical company dedicated to the discovery and development of ...

InFocus: Life Sciences & Healthcare e-newsletter - April 2011

Welcome to the April issue of InFocus, our life sciences and healthcare e-newsletter. In this issue we look at: ...

Pharma & Social Media - PMCPA takes the plunge (and beats the FDA)

The Prescription Medicines Code of Practice Authority (PMCPA) has issued informal guidance on the use of digital communications ...

When taking a medicine off the shelves infringes competition law

At a time when industry experts are talking about the death of the blockbuster drug, product lifecycle management strategies are ...

The EU Patent and the European and EU Patents Court - an update

Following the CJEU opinion on the unified patent litigation system on the 8 March and the European Council vote on the unified ...

Budget 2011 – Chancellor confirms details of “Patent Box” and other corporate tax reforms – further consultations in May

As we reported in the January issue of InFocus the long anticipated document entitled “Corporate Tax Reform” was published by the ...

Regulation - in the Spotlight

The courts’ focus on industry strategies could mean some practices are deemed infringements of competition law It is well known ...

Surfing the social media wave

In the Surfing the social media wave (published by Scrip 100 on January 7th 2011) Tim Worden talks about some of the social media ...

InFocus: Life Sciences & Healthcare e-newsletter - January 2011

Welcome to the January 2011 edition of InFocus, the Life Sciences and Healthcare newsletter. This month we discuss: Sold Out - ...

Pharma and Social Media – What Does 2011 Hold?

2010 was the year in which the FDA had said they would issue some guidance on the use of social media by pharma.  It was ...

More heartburn for the pharma sector

The European Commission has escalated its crackdown on the pharma sector, conducting dawn raids yesterday on the originator ...

MPF award for Taylor Wessing's commitment to sustainability

Taylor Wessing is celebrating after winning the Sustainability Reporting category at the prestigious MPF European Practice ...

Pharma and social media: an uneasy marriage?

Despite being the fastest growing marketing medium for many industries, social media channels present major legal and regulatory ...

Taylor Wessing advises on new financing to enhance novel stent technology

The venture capital and life sciences groups at industry leading law firm, Taylor Wessing LLP, have advised new client, Seroba ...

Tentative Steps - A plain legal guidance framework will empower the move to online opportunities

In 2009, pharma first dipped its toe into the uncertain waters of social media. With luck, in 2010 some guidance will emerge from ...

Taylor Wessing advises Myotec Therapeutics on £5.6m funding round

Leading law firm Taylor Wessing has advised Myotec Therapeutics Ltd, the Cambridge based speciality pharmaceutical company, on ...

£65m funding raised by leading pharma company Archimedes

A team of private equity, employment and tax lawyers from Taylor Wessing has advised the management of the speciality pharma ...

Generic Substitution - UK Department of Health Consultation

The UK government announced plans to introduce generic substitution in the Pharmaceutical Price Regulation Scheme (PPRS) 2009. On ...

InFocus - Life Sciences & Healthcare e-newsletter - January 2010

Life Sciences & Healthcare Update - December 2009

EU moves closer to Biosimilar antibodies

Patents and the EU medtech sector: a slumbering volcano

Tim Worden discusses the patent situation regarding medical devices in the EU in this article written by Faraz Kermani for the ...

ECJ boost for borderline Products

Protection for DNA-based claims in Europe

The MHRA Investigation into GSK's Reporting of Adverse Events in Seroxat Paediatric Clinical Trials

Interim Injunctions in the UK - Recent Pharma Cases in the Patents Court

Can SPC's have a zero or negative term?

Taylor Wessing advises Innate Pharma on the in-licence of a phase 1 monoclonal antibody from Novo Nordisk

Taylor Wessing's Life Sciences & Healthcare Group has advised Innate Pharma (IPH) on an agreement with Novo Nordisk, in which ...

Out of circulation: No trade mark infringement of goods in transit